The Plasma Proteome and Risk of Future Venous Thromboembolism—Results from the HUNT Study in Thrombosis and Haemostasis

Publikationsverlauf

Eingereicht: 03. April 2025

Angenommen: 04. April 2025

Artikel online veröffentlicht:
25. April 2025

• References

• 1 Mersha TB. From Mendel to multi-omics: shifting paradigms. Eur J Hum Genet 2024; 32 (02) 139-142
• 2 Lander ES, Linton LM, Birren B. et al; International Human Genome Sequencing Consortium. Initial sequencing and analysis of the human genome. Nature 2001; 409 (6822) 860-921
• 3 Roberts DS, Loo JA, Tsybin YO. et al. Top-down proteomics. Nat Rev Methods Primers 2024; 4 (01) 38
• 4 Dai X, Shen L. Advances and trends in omics technology development. Front Med (Lausanne) 2022; 9: 911861
• 5 Dayon L, Cominetti O, Affolter M. Proteomics of human biological fluids for biomarker discoveries: technical advances and recent applications. Expert Rev Proteomics 2022; 19 (02) 131-151
• 6 Timp W, Timp G. Beyond mass spectrometry, the next step in proteomics. Sci Adv 2020; 6 (02) eaax8978
• 7 Silverstein MD, Heit JA, Mohr DN, Petterson TM, O'Fallon WM, Melton III LJ. Trends in the incidence of deep vein thrombosis and pulmonary embolism: a 25-year population-based study. Arch Intern Med 1998; 158 (06) 585-593
• 8 Roy DC, Wang TF, Lun R. et al. Circulating blood biomarkers and risk of venous thromboembolism in cancer patients: a systematic review and meta-analysis. Thromb Haemost 2024; 124 (12) 1117-1133
• 9 De Corte P, Milhoranca I, Mechsner S, Oberg AS, Kurth T, Heinemann K. Unravelling the causal relationship between endometriosis and the risk for developing venous thromboembolism: a pooled analysis. Thromb Haemost 2025; 125 (04) 385-394
• 10 Huang Z, Zheng Z, Pang L. et al. The association between obstructive sleep apnea and venous thromboembolism: a bidirectional two-sample Mendelian randomization study. Thromb Haemost 2024; 124 (11) 1061-1074
• 11 Lanting VR, Takada T, Bosch FTM. et al. Risk of recurrent venous thromboembolism in patients with cancer: an individual patient data meta-analysis and development of a prediction model. Thromb Haemost 2025; 125 (06) 589-596
• 12 Granat LM, Li H, Ondeck M. et al. Venous thromboembolism post-allogeneic hematopoietic cell transplant: risk factors, incidence, and outcomes. Thromb Haemost 2025; 125 (02) 155-162
• 13 Liang B, Zha L, Peng B. et al. Association of cardiovascular health with the incidence of venous thromboembolism: a prospective study of 275,149 participants from the UK Biobank. Thromb Haemost 2024; 124 (10) 948-957
• 14 Danilatou V, Dimopoulos D, Kostoulas T, Douketis J. Machine learning-based predictive models for patients with venous thromboembolism: a systematic review. Thromb Haemost 2024; 124 (11) 1040-1052
• 15 Gade IL, Riddersholm SJ, Stilling-Vinther T, Brøndum RF, Bennike TB, Honoré B. A clinical proteomics study of exhaled breath condensate and biomarkers for pulmonary embolism. J Breath Res 2023; 18 (01) 016007
• 16 Granholm F, Bylund D, Shevchenko G, Lind SB, Henriksson AE. A feasibility study on the identification of potential biomarkers in pulmonary embolism using proteomic analysis. Clin Appl Thromb Hemost 2022 ;28:10760296221074347
• 17 Jensen SB, Latysheva N, Hindberg K, Ueland T. Plasma lipopolysaccharide-binding protein is a biomarker for future venous thromboembolism: results from discovery and validation studies. J Intern Med 2022; 292 (03) 523-535
• 18 Ten Cate V, Prochaska JH, Schulz A. et al. Protein expression profiling suggests relevance of noncanonical pathways in isolated pulmonary embolism. Blood 2021; 137 (19) 2681-2693
• 19 Ganesh SK, Sharma Y, Dayhoff J. et al. Detection of venous thromboembolism by proteomic serum biomarkers. PLoS One 2007; 2 (06) e544
• 20 Rietveld IM, Lijfering WM, le Cessie S. et al. High levels of coagulation factors and venous thrombosis risk: strongest association for factor VIII and von Willebrand factor. J Thromb Haemost 2019; 17 (01) 99-109
• 21 Yuan S, Titova OE, Zhang K. et al. Plasma protein and venous thromboembolism: prospective cohort and mendelian randomisation analyses. Br J Haematol 2023; 201 (04) 783-792
• 22 Skates SJ, Gillette MA, LaBaer J. et al. Statistical design for biospecimen cohort size in proteomics-based biomarker discovery and verification studies. J Proteome Res 2013; 12 (12) 5383-5394
• 23 Kwon YW, Jo HS, Bae S. et al. Application of proteomics in cancer: recent trends and approaches for biomarkers discovery. Front Med (Lausanne) 2021; 8: 747333
• 24 Xiao GG, Recker RR, Deng HW. Recent advances in proteomics and cancer biomarker discovery. Clin Med Oncol 2008; 2: 63-72
• 25 Suran M. After the genome—a brief history of proteomics. JAMA 2022; 328 (12) 1168-1169
• 26 Demichev V, Tober-Lau P, Nazarenko T. et al; PA-COVID-19 Study group. A proteomic survival predictor for COVID-19 patients in intensive care. PLOS Digit Health 2022; 1 (01) e0000007
• 27 Zhong W, Altay O, Arif M. et al. Next generation plasma proteome profiling of COVID-19 patients with mild to moderate symptoms. EBioMedicine 2021; 74: 103723
• 28 Forrer A, Schoenrath F, Torzewski M. et al. Novel blood biomarkers for a diagnostic workup of acute aortic dissection. Diagnostics (Basel) 2021; 11 (04) 615
• 29 Marto JP, Carvalho ASG. G Mollet I, et al. Proteomics to identify new blood biomarkers for diagnosing patients with acute stroke. J Am Heart Assoc 2023; 12 (22) e030021
• 30 Gustafsson S, Lampa E, Jensevik Eriksson K. et al. Markers of imminent myocardial infarction. Nat Cardiovasc Res 2024; 3 (02) 130-139
• 31 Oved K, Cohen A, Boico O. et al. A novel host-proteome signature for distinguishing between acute bacterial and viral infections. PLoS One 2015; 10 (03) e0120012
• 32 D'Onofrio V, Heylen D, Pusparum M. et al. A prospective observational cohort study to identify inflammatory biomarkers for the diagnosis and prognosis of patients with sepsis. J Intensive Care 2022; 10 (01) 13
• 33 Strehlow M, Gisondi MA, Caretta-Weyer H. et al. 2023 Society for Academic Emergency Medicine Consensus Conference on Precision Emergency Medicine: development of a policy-relevant, patient-centered research agenda. Acad Emerg Med 2024; 31 (08) 805-816
• 34 Kavallaris M, Marshall GM. Proteomics and disease: opportunities and challenges. Med J Aust 2005; 182 (11) 575-579
• 35 Thibord F, Klarin D, Brody JA. et al; Global Biobank Meta-Analysis Initiative; Estonian Biobank Research Team; 23andMe Research Team; Biobank Japan; CHARGE Hemostasis Working Group. Cross-ancestry investigation of venous thromboembolism genomic predictors. Circulation 2022; 146 (16) 1225-1242
• 36 Katz DH, Robbins JM, Deng S. et al. Proteomic profiling platforms head to head: Leveraging genetics and clinical traits to compare aptamer- and antibody-based methods. Sci Adv 2022; 8 (33) eabm5164
• 37 Cui M, Cheng C, Zhang L. High-throughput proteomics: a methodological mini-review. Lab Invest 2022; 102 (11) 1170-1181
• 38 Zöller B, Svensson PJ, Dahlbäck B, Lind-Hallden C, Hallden C, Elf J. Genetic risk factors for venous thromboembolism. Expert Rev Hematol 2020; 13 (09) 971-981
• 39 Flores JE, Claborne DM, Weller ZD, Webb-Robertson BM, Waters KM, Bramer LM. Missing data in multi-omics integration: recent advances through artificial intelligence. Front Artif Intell 2023; 6: 1098308
• 40 Kang M, Ko E, Mersha TB. A roadmap for multi-omics data integration using deep learning. Brief Bioinform 2022; 23 (01) bbab454